EHA 2021 Top Pick #5: Pirtobrutinib (Loxo-305), A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 Bruin Study

You are here: